NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025

Rhea-AI Summary

NeurAxis (NYSE: NRXS) will release its third quarter 2025 financial results for the period ended September 30, 2025, on Tuesday, November 11, 2025 before market open.

The company will host a conference call and live webcast the same day at 9:00 a.m. Eastern Time. Webcast access and a replay will be available in the Investor Relations section at https://ir.neuraxis.com/ and at the provided media-server link. Participants may submit questions via the webcast portal or by emailing NRXS@lythampartners.com.

Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time

CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its third quarter 2025, for the period ended September 30, 2025, on Tuesday, November 11, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 11, 2025, at 9:00 am ET to review the results.

Conference Call Details

Date and Time: Tuesday, November 11, 2024, at 9:00am ET

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/uat4r9m5/. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com.

Call-in Information: Interested parties can also access the live conference call by initially registering at the following Call In Link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.

Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/uat4r9m5/.

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contacts:

Company
NeurAxis, Inc.
info@neuraxis.com

Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

FAQ

When will NeurAxis (NRXS) report third quarter 2025 results?

NeurAxis will release Q3 2025 results for the period ended September 30, 2025, on Tuesday, November 11, 2025 before market open.

What time is the NeurAxis (NRXS) Q3 2025 conference call?

The conference call and live webcast are scheduled for 9:00 a.m. Eastern Time on November 11, 2025.

How can investors join the NeurAxis (NRXS) live webcast for Q3 2025 results?

Access the live webcast via the Investor Relations page at https://ir.neuraxis.com/ or the media-server link provided in the announcement.

How do I submit questions during the NeurAxis (NRXS) Q3 2025 call?

Questions can be sent through the webcast portal using the “Ask a Question” link or emailed to NRXS@lythampartners.com.

Will a replay of the NeurAxis (NRXS) Q3 2025 call be available?

Yes. A webcast replay will be posted in the Investor Relations section at https://ir.neuraxis.com/ and the media-server link.

Is there a phone option to join the NeurAxis (NRXS) Q3 2025 call?

Yes. Phone participants must register via the call-in registration link to receive dial-in details and a unique PIN by email.